
Loading, please wait...

Loading, please wait...

Physicians recently identified a rare case of neonatal mesenchymal hamartoma in the right ventricle of a newborn infant. This condition is particularly unusual because most documented cases typically occur in the left ventricle. Consequently, the mass led to significant clinical complications, including pericardial effusion and cardiac tamponade shortly after birth. Because early diagnosis is vital, this case highlights the critical role of advanced imaging in neonatal cardiology.
Clinicians initially suspected the cardiac mass during prenatal screenings. However, the definitive diagnosis required comprehensive postnatal investigation using advanced diagnostic tools. Specifically, cardiac MRI provided detailed visualization of the right ventricular mass and its relationship with surrounding cardiac structures. Furthermore, histopathological analysis confirmed the tumor as a mesenchymal hamartoma. Because these tumors can cause life-threatening hemodynamic instability, prompt recognition and characterization are essential for improving neonatal survival rates.
While many cardiac tumors in neonates are histologically benign, their location often dictates the severity of clinical symptoms. Specifically, a right ventricular mass can obstruct blood flow or lead to rapid fluid accumulation in the pericardial sac. Therefore, a multidisciplinary team including neonatologists and cardiothoracic surgeons must manage such cases with urgency. Treatment strategies typically focus on relieving intrapericardial pressure and preventing further cardiac compromise. Additionally, long-term monitoring ensures that the patient remains stable following initial stabilization or surgical intervention.
Symptoms often include respiratory distress, cyanosis, and poor feeding. In severe cases, signs of cardiac tamponade such as hypotension and muffled heart sounds may appear.
Physicians primarily use echocardiography and cardiac MRI to assess tumor morphology and location. However, histopathology remains the gold standard for distinguishing mesenchymal hamartomas from rhabdomyomas or fibromas.
Surgery is usually necessary if the mass causes hemodynamic obstruction, life-threatening arrhythmias, or persistent pericardial effusion. Asymptomatic cases may occasionally be managed with close observation.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Explore a rare case of neonatal right ventricular mesenchymal hamartoma causing cardiac tamponade, highlighting the roles of MRI and histopathology in diagn...
8 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today